Expression of the High-Affinity Fluoropyrimidine-Preferring Nucleoside Transporter hCNT1 Correlates with Decreased Disease-Free Survival in Breast Cancer-Reference-Cited by-同舟云学术

Expression of the High-Affinity Fluoropyrimidine-Preferring Nucleoside Transporter hCNT1 Correlates with Decreased Disease-Free Survival in Breast Cancer

Published:2006 Issue:3 Volume:70 Page:238-244
ISSN:0030-2414
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Gloeckner-Hofmann Katharina,Guillén-Gómez Elena,Schmidtgen Claudia,Porstmann Romy,Ziegler Ralf,Stoss Oliver,Casado F. Javier,Rüschoff Josef,Pastor-Anglada Marçal

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Reference34 articles.

1. Potential of Xeloda^® in Colorectal Cancer and Other Solid Tumors

2. Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine Capecitabine in Combination With Paclitaxel in Patients With Advanced Solid Malignancies

3. Capecitabine, an Oral Fluoropyrimidine Carbamate With Substantial Activity in Advanced Colorectal Cancer: Results of a Randomized Phase II Study

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nucleoside transporters and immunosuppressive adenosine signaling in the tumor microenvironment: Potential therapeutic opportunities;Pharmacology & Therapeutics;2022-12

2. Re-Discovery of Pyrimidine Salvage as Target in Cancer Therapy;Cells;2022-02-20

3. Emerging Roles of Nucleoside Transporters;Frontiers in Pharmacology;2018-06-06

4. Role of drug-dependent transporter modulation on the chemosensitivity of cholangiocarcinoma;Oncotarget;2017-10-06

5. FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia;Oncotarget;2016-07-06